| Targets |
MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 does not have a direct biological target, as it is a synthetic conjugate used for the construction of antibody neoDegrader conjugates (AnDC). Its function is to serve as a neodegrader building block that enables the targeted degradation of specific proteins when incorporated into AnDC molecules. The compound is a chemical tool for the development of novel therapeutic modalities targeting protein degradation pathways.
|
|---|---|
| ln Vitro |
In vitro activity of MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 is demonstrated by its function as a neodegrader conjugate in the synthesis of antibody neoDegrader conjugates (AnDC). The resulting AnDC molecules are evaluated for their ability to bind to target antigens and induce degradation of specific proteins. The compound's role as a building block enables the construction of targeted protein degraders for research applications. Detailed activity data for the conjugate itself are not available, as it is an intermediate.
|
| ln Vivo |
In vivo activity of MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 is not directly applicable, as the compound is a synthetic intermediate used in AnDC synthesis rather than a therapeutic agent itself. The activity of AnDC molecules synthesized using this conjugate would be evaluated in vivo. These AnDCs are designed for targeted protein degradation in cancer and other diseases. Detailed in vivo data for AnDCs incorporating this conjugate are not available from the search results.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 is not applicable, as the compound is a synthetic intermediate rather than a pharmacologically active agent. The synthesis and characterization of AnDCs using this conjugate involve chemical conjugation reactions rather than biological assays. The purity and functionality of the conjugate are assessed using analytical chemistry methods such as HPLC and mass spectrometry, with a reported purity of 99.63%.
|
| Cell Assay |
In vitro cell-based assays for MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 are not directly applicable, as the compound is a synthetic intermediate used in AnDC synthesis. However, AnDC molecules synthesized using this conjugate would be evaluated in cell-based assays to assess their binding affinity to target antigens, internalization, and efficacy in inducing target protein degradation. Standard protocols include antigen binding assays, flow cytometry, and protein degradation assays by Western blot.
|
| Animal Protocol |
In vivo animal studies for MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 are not directly applicable, as the compound is a synthetic intermediate used in AnDC synthesis. AnDC molecules synthesized using this conjugate would be evaluated in xenograft mouse models to assess tumor growth inhibition, pharmacokinetics, and toxicity. Standard protocols include administration of the AnDC, monitoring of tumor volume, and assessment of body weight and clinical signs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 include a molecular weight of 1133.55 g/mol and a molecular formula of C53H61ClN8O18. The compound appears as a white to off-white solid with 99.63% purity. As a synthetic intermediate, detailed pharmacokinetic parameters are not applicable. Storage recommendations include conditions specified in the Certificate of Analysis. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity information for MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 is limited. As a research-use compound, standard safety precautions for handling should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 (Compound Ie) is a neodegrader conjugate for the synthesis of antibody neoDegrader conjugates (AnDC). It has a molecular weight of 1133.55 g/mol and formula C53H61ClN8O18. It appears as a white to off-white solid with 99.63% purity. It is intended for research use only and is not for human therapeutic applications.
|
| Molecular Formula |
C53H61CLN8O18
|
|---|---|
| Molecular Weight |
1133.55
|
| CAS # |
2722697-86-9
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~88.22 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8822 mL | 4.4109 mL | 8.8218 mL | |
| 5 mM | 0.1764 mL | 0.8822 mL | 1.7644 mL | |
| 10 mM | 0.0882 mL | 0.4411 mL | 0.8822 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
